AmoyDx(SZ:300685) Xin Lang Cai Jing·2025-10-31 06:04Core Insights - The stock price of Aide Biological increased by 2.00% on October 31, reaching 22.95 CNY per share, with a market capitalization of 8.986 billion CNY [1] - The company reported a revenue of 866 million CNY for the first nine months of 2025, reflecting a year-on-year growth of 2.08%, and a net profit of 263 million CNY, up 15.50% year-on-year [2] - Aide Biological's main business includes the development, production, and sales of molecular diagnostic products for precision oncology, with testing reagents accounting for 83.43% of revenue [1] Financial Performance - As of September 30, 2025, Aide Biological had 26,600 shareholders, an increase of 5.23% from the previous period, with an average of 14,628 circulating shares per shareholder, down 4.97% [2] - Cumulative cash dividends since the company's A-share listing amount to 421 million CNY, with 232 million CNY distributed over the last three years [3] Shareholding Structure - As of September 30, 2025, Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 35.3892 million shares, an increase of 3.7186 million shares from the previous period [3] - The fifth-largest circulating shareholder, Huabao CSI Medical ETF, holds 7.7022 million shares, a decrease of 1.3344 million shares from the previous period [3] - The tenth-largest circulating shareholder, Southern CSI 1000 ETF, holds 2.5088 million shares, marking a new entry [3]